MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, OCUL had $344,958K increase in cash & cash equivalents over the period. -$216,893K in free cash flow.

Cash Flow Overview

Change in Cash
$344,958K
Free Cash flow
-$216,893K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
Revenue
51,951
Cost of product revenue
6,574
Direct program expenses, axpaxli for wet amd
119,609
Direct program expenses, axpaxli for npdr
4,804
Direct program expenses, other clinical and preclinical programs
3,582
Unallocated expenses, personnel costs
39,255
Unallocated expenses, all other costs
7,527
Selling & marketing
48,510
General & administrative
37,377
Facilities
7,223
Stock-based compensation
43,184
Depreciation
4,323
Interest income
18,355
Interest expense
11,835
Other non-operating items
-2,442
Net loss
-265,939
Stock-based compensation expense
43,184
Non-cash interest expense
3,397
Change in fair value of derivative liabilities
-2,471
Depreciation and amortization expense
4,323
Gains and losses on disposal of items of property and equipment
29
Accounts receivable, net
-1,738
Prepaid expenses and other current assets
-2,602
Inventory
524
Accounts payable
-887
Operating lease assets
-1,307
Accrued expenses
5,248
Deferred revenue
-128
Operating lease liabilities
-1,646
Net cash used in operating activities
-204,883
Purchases of property and equipment
12,010
Proceeds from sales of property and equipment
130
Net cash used in investing activities
-11,880
Proceeds from exercise of stock options
20,544
Proceeds from issuance of common stock pursuant to employee stock purchase plan
1,592
Proceeds from issuance of common stock upon public offering, net of issuance costs
539,585
Net cash provided by financing activities
561,721
Net increase in cash, cash equivalents and restricted cash
344,958
Cash and cash equivalents at beginning of period
393,716
Cash and cash equivalents at end of period
738,674
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

OCULAR THERAPEUTIX, INC (OCUL)

OCULAR THERAPEUTIX, INC (OCUL)